Antimicrobial drug use and the risk of glioma: A case–control study-Reference-Cited by-同舟云学术

Antimicrobial drug use and the risk of glioma: A case–control study

Published:2022-09-06 Issue:3 Volume:12 Page:3684-3695
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Haedenkamp Tareq M.¹^ORCID,Leitzmann Michael F.²,Linker Ralf A.¹,Meier Christoph³⁴⁵,Becker Claudia³⁵,Jick Susan⁴⁶,Hau Peter¹^ORCID,Seliger Corinna⁷^ORCID

Affiliation:

1. Wilhelm Sander‐NeuroOncology Unit and Department of Neurology Regensburg University Hospital Regensburg Germany

2. Institute of Epidemiology and Preventive Medicine Regensburg University Hospital Regensburg Germany

3. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences University of Basel Basel Switzerland

4. Boston Collaborative Drug Surveillance Program Lexington MA USA

5. Hospital Pharmacy, University Hospital Basel Basel Switzerland

6. Boston University School of Public Health Lexington MA USA

7. Department of Neurology Heidelberg University Hospital Heidelberg Germany

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5222

Reference49 articles.

1. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

2. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018

3. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

4. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

5. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial